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Many neurological disorders, including neurodevelopmental disorders, report
hypersynchrony of neuronal networks. These alterations in neuronal synchronization
suggest a link to the function of inhibitory interneurons. In Fragile X Syndrome (FXS), it
has been reported that altered synchronization may underlie hyperexcitability, cognitive
dysfunction and provide a link to the increased incidence of epileptic seizures. Therefore,
understanding the roles of inhibitory interneurons and how they control neuronal networks
is of great importance in studying neurodevelopmental disorders such as FXS. Here, we
present a review of how interneuron populations and inhibition are important contributors
to the loss of excitatory/inhibitory balance seen in hypersynchronous and hyperexcitable
networks from neurodevelopmental disorders, and specifically in FXS.
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INTRODUCTION
Fragile X Syndrome (FXS) is one of several disorders associated
with autism spectrum disorders (ASDs)—a heterogeneous group
of behaviorally identified neurodevelopmental disabilities. The
prevalence rate of autism in FXS reportedly ranges from 25%
to 52% (Kaufmann et al., 2004; García-Nonell et al., 2008; Hall
et al., 2008), often presenting ASD features such as social avoid-
ance (Marco and Skuse, 2006). Also, FXS is the most common
inherited cause of intellectual disability with an average IQ of
40 (Merenstein et al., 1996). Because of its association to the X
chromosome, FXS has a higher prevalence in males as approxi-
mately of 1 in 3600–4000, than females (approximately 1 in 4000–
6000) (Coffee et al., 2009). FXS is attributed to the transcrip-
tional silencing of the Fragile X Mental Retardation 1 (FMR1)
gene and the consequent loss of the gene product of FMR1—
Fragile X Mental Retardation Protein (FMRP; Penagarikano et al.,
2007). In the human condition the silencing of FMR1 is caused
by hypermethylation—this occurs when a trinucleotide (CGG)
repeat located in the 5’ untranslated region of the gene expands
to a length of more than 200 repeats. The loss of this protein is
far reaching because FMRP interacts with approximately 4–8%
of all synaptic mRNAs and regulates the translation of numerous
synaptic proteins and receptor systems (Brown et al., 2001).
The FXS phenotype involves hyperactivity, attention deficits,
poor eye contact, shyness, self-talk, anxiety, mood instabil-
ity, hyperarousal to sensory stimuli, and autism (Hagerman
and Hagerman, 2002). Defects underlying neurodevelopmental
disorders, including FXS, are widely believed to lie at the level
of the synapse (Zoghbi, 2003; Ebert and Greenberg, 2013). In
FXS, these profound changes include alterations in both exci-
tatory and inhibitory neurotransmission across multiple brain
regions (Huber et al., 2002; Bear et al., 2004; Bureau et al.,
2008; Harlow et al., 2010; Olmos-Serrano et al., 2010; Till et al.,
2012; Van der Molen et al., 2012; Kim et al., 2013). Although
excitatory/inhibitory balance has been a recent subject of study in
FXS research, not much is known of how interneuron populations
contribute to the phenotype. In this review, we summarize current
knowledge of FXS behavioral and cognitive phenotype, the cir-
cuitry abnormalities related to them and how interneurons are an
important subject of study to understand alterations in neuronal
networks.
COGNITION AND BEHAVIORAL PROCESSING IN FXS
Since the FMR1 gene was first identified and linked to FXS in
1991 (Verkerk et al., 1991), tremendous progress has been made
to understand the neurological deficits that contribute to the
phenotype. Most of the cognition and behavioral abnormalities
have been investigated to try to understand how FMRP is involved
in the neurobiological processing of brain areas related to these
specific tasks. For instance, lack of FMRP found in the mouse
model of FXS leads to cerebellar deficits at both the cellular
and behavioral levels and raise the possibility that cerebellar
dysfunctions can contribute to motor learning deficits in FXS
patients (Koekkoek et al., 2005). Indeed, although premutation
Frontiers in Cellular Neuroscience www.frontiersin.org August 2014 | Volume 8 | Article 245 | 1
Cea-Del Rio and Huntsman Interneuron dysfunction in FXS
carriers of FMRP lead to a different syndrome (FXTAS), they
showed an absence of cerebellar inhibition over primary motor
cortex and a reduced GABA-mediated intracortical and afferent
inhibition compared with healthy individuals (Conde et al., 2013)
that could potentially also be present in FXS patients. More-
over, FXS patients display specific emotion recognition deficits
for angry and neutral (but not happy or fearful) facial expres-
sions through visual scanning tasks (Shaw and Porter, 2013),
that in turn is directly related to formation and function of
neuronal circuits attributed to behavioral processes such as fear,
emotion recognition and anxiety carried out by the amygdala
(Olmos-Serrano and Corbin, 2011; Kim et al., 2014). These
socio-emotional deficits are also associated with deficits in neu-
ronal processing of sensory systems. Studies have shown that
together with a shift change in development for synaptic for-
mation and plasticity in the amygdala (Kratovac and Corbin,
2013; Vislay et al., 2013), impaired critical plasticity periods
for auditory, visual and somatosensory cortex also occurred
in FXS (Bureau et al., 2008; Harlow et al., 2010; Till et al.,
2012; Van der Molen et al., 2012; Kim et al., 2013). Therefore
these studies reveal a role for FMRP in shaping sensory cir-
cuits during developmental critical periods when time windows
of protein expression are vulnerable to alterations (reviewed
in Meredith et al., 2012). Dendritic spine stability, branching
and density abnormalities are part of the developmental delay
observed in these same brain areas (Cruz-Martín et al., 2010;
Pan et al., 2010; Till et al., 2012; Lauterborn et al., 2013) and
they depend on the environmental context and experience that
they are undergoing. Other characteristics of cortical neuronal
networks in FXS are hyperesponsivness and hyperexcitability
(Gonçalves et al., 2013; Rotschafer and Razak, 2013), making
these circuits highly synchronous which taken together suggest
excitatory/inhibitory balance abnormalities of the FXS neuronal
circuitry. These state-dependent network defects could explain
the intellectual and sensory integration dysfunctions associated
with FXS.
EXCITATORY/INHIBITORY BALANCE IN FXS NEURONAL
NETWORKS
FXS neuronal networks are hyperexcitable (Gibson et al., 2008;
Olmos-Serrano et al., 2010; Gonçalves et al., 2013; Rotschafer and
Razak, 2013). This explains why most studies focus on excessive
excitatory activity. The majority of research about excitatory drive
and synaptic plasticity that describes hyperexcitability in FXS is
illustrated in the “mGluR theory” (Huber et al., 2002; Bear et al.,
2004). Briefly, the mGluR theory explains that the psychiatric
and neurological aspects of FXS are a consequence of exag-
gerated responses to metabotropic glutamate receptor (mGluR)
activation (Huber et al., 2002). One response is mediated by
a synaptic plasticity process known as long term depression
(LTD; Huber et al., 2002; Bear et al., 2004). Additional studies
also reveal that pharmacological intervention of mGluR activa-
tion can rescue the FXS phenotype in the Fmr1 mouse model
suggesting a therapeutic role for inhibitors of mGluR activity-
specifically type 1 and type 5 receptor activity (Dölen et al.,
2007; Michalon et al., 2012; Ronesi et al., 2012). Due to ini-
tial early success of 2-methyl-6-(phenylethynyl)pyridine (MPEP),
fenobam and 2-chloro-4-((2,5-dimethyl-1-(4-(trifluoromethoxy)
phenyl)-1H-imidazol-4-yl)ethynyl)pyridine (CTEP), the use of
mGluR5 antagonists remains a primary treatment option for FXS
(Porter et al., 2005; Yan et al., 2005; Lindemann et al., 2011). How-
ever, additional attempts at specific targeting of these receptors
have been problematic. Despite mixed success, the development
of the mGluR5 antagonist Mavoglurant (AFQ056) has recently
been discontinued (April 2014) due to a failure to show improve-
ment over placebo-controlled trials.
Nevertheless, other synaptic proteins have also been involved
in the pathology of the syndrome. For instance, loss of FMRP
leads to impairments in NMDA receptor-dependent synaptic
plasticity in the dentate gyrus (DG), but not in the cornu ammo-
nis area 1 (CA1) subregion (Bostrom et al., 2013), suggesting that
functional expression of proteins could be region or even synapse-
specific. Additionally, astroglial cells may potentially contribute
to enhanced neuronal excitability observed in the mouse model
of FXS due to a reduced uptake of glutamate (Higashimori et al.,
2013).
On the other hand, we have to account for the excitatory
stream counterpart, inhibition, and how this balances circuit
activity. Several components of the GABAergic system are also
regulated by FMRP expression (reviewed in Paluszkiewicz et al.,
2011a). While there is evidence that GABAA receptor subunits
show enhanced surface expression such as the γ2 subunit (Liu
et al., 2013), most other studies suggest the contrary, showing that
mRNA expression of α1, α3 and α4β1 and β2, and γ1 and γ2, and
δ GABAA receptor subunits in the hippocampus (D’Hulst et al.,
2006) and the δ subunit in neocortex (Gantois et al., 2006) are
down regulated in Fmr1 KO mice. Further evidence shows that
FMRP binds δ subunit mRNA, suggesting a direct influence of
FMRP on the expression of δ subunits (Gantois et al., 2006). This
latter study supports the hypothesis that tonic inhibition, which
is partially mediated by δ subunit containing GABAA receptors,
is also down-regulated, contributing to hyperexcitability abnor-
malities in the neuronal networks of Fmr1 KO mice (Gantois
et al., 2006; Olmos-Serrano et al., 2010; Martin et al., 2014). Thus,
GABAergic tonic inhibition has been also taken as a potential
candidate for therapeutic treatment in FXS (Olmos-Serrano et al.,
2010, 2011; Heulens et al., 2012; Martin et al., 2014).
Despite this information on excitatory/inhibitory balance
abnormalities in FXS, an important contributor to the balance has
been neglected in these studies: the functional and anatomically
diverse population of inhibitory interneurons. Although there is
information on how GABAA receptors are affected by the lack
of FMRP, few studies address dysfunction of specific presynaptic
inhibitory interneurons in FXS. Here we want to summarize some
of these studies and discuss how the specific functional properties
of different subclasses of inhibitory interneurons are relevant to
the study of FXS.
THE CONTRIBUTION OF INHIBITORY INTERNEURONS TO THE
FXS PHENOTYPE
Although often overlooked, the importance of local circuit
inhibitory interneurons has rapidly gained attention thanks to
a number of studies that have provided essential electrophysi-
ological, anatomical and synaptic insight into the function and
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role(s) played by this large and heterogeneous cell population
(Buzsáki et al., 1992; Gulyás et al., 1993a,b; Buhl et al., 1994;
Miles et al., 1996; Gupta et al., 2000; Markram et al., 2004).
At the most basic level, interneurons are considered to provide
inhibitory control over the excitatory flow of the neuronal net-
work. Their physiological properties and connectivity allow them
to control the rhythmic output of large populations of excita-
tory principal cells as well as other populations of inhibitory
interneurons (Cobb et al., 1995; Freund and Katona, 2007;
Klausberger and Somogyi, 2008). Interneuronal physiological
responses in vivo often occur in a time-locked form, discharg-
ing in the same temporal window of their preferential oscil-
latory frequency, suggesting their direct involvement in the
synchronization and control of pyramidal cells firing (Klaus-
berger and Somogyi, 2008). Thus, it is possible that interneu-
ron subtypes show a differential participation in the FXS
phenotype and likely contribute to specific pathophysiological
properties of the neuronal networks where they are involved
(Figure 1).
As earlier stated, cortical networks in FXS are hyperexcitable
and highly synchronous (Gonçalves et al., 2013; Rotschafer
and Razak, 2013). This could explain state-dependent network
defects related to intellectual disability, increased incidence of
seizures and sensory integration dysfunctions associated with FXS
(reviewed in Musumeci et al., 1999; Hagerman and Stafstrom,
2009; Hagerman et al., 2009). Based on heterogeneous anatomy
and function of inhibitory interneurons it is likely that inhibitory
circuits play important roles in this phenotype. For example,
both perisomatic and dendritic-targeting interneurons are known
to be involved in the hyperexcitability of the network. Peri-
somatic interneurons mainly control pyramidal cell excitability
by regulating Na+-dependent action potential initiation (Freund
and Katona, 2007). In contrast, inhibition arriving at dendritic
locations likely have little influence over somal action poten-
tial generation but strongly affect local dendritic integration
and regulates dendritic Ca2+-dependent spike initiation and/or
propagation (Miles et al., 1996). From this point of view, while
perisomatic interneurons have a role in the synchronization of
FIGURE 1 | Comparative table for interneuron populations in FXS. Three
different interneuron types (FS: Fast spiking; LTS: Low threshold spiking and
NGF: Neurogliaform cells) are compared here regarding their
circuitry/connectivity (left panel), oscillatory preferences (left middle panel),
electrical properties (right middle panel) and what their failure would
represent in FXS (right panel).
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network circuits imposing a rhythm, dendritic-targeting cells
mainly participate in the propagation of synchronized activity
waves throughout the network.
In FXS, EEG recordings show elevated relative theta power and
reduced relative upper-alpha power (Van der Molen and Van der
Molen, 2013), which can be related to longer UP states seen in
the neocortex of Fmr1 KO mouse model (Gibson et al., 2008;
Hays et al., 2011). Indeed, local excitation of fast-spiking (FS)
inhibitory interneurons, a perisomatic-targeting interneuron that
engage preferably in frequencies between 40–100 Hz (Klausberger
et al., 2003), is robustly decreased in neocortex in Fmr1 KO mice
(Selby et al., 2007; Patel et al., 2013), which could explain the
decrease in synchrony in gamma frequency (Gibson et al., 2008)
of the network (Figure 1). However, these inhibitory deficiencies
seem to be mediated by polysynaptic responses through local
cortical connections instead of monosynaptic or feed-forward
responses mediated by thalamic fiber stimulation (Gibson et al.,
2008). This is further explained by Patel et al. (2013). When
FMRP is conditionally knocked-out in excitatory or inhibitory
presynaptic cells, paired recordings reveal that only excitatory
responses in inhibitory FS interneurons were decreased by the loss
of FMRP (Patel et al., 2013). On the other hand, low threshold
spiking (LTS) interneurons, a dendritic-targeting interneuron
that contributes to the synchronization of neuronal networks
over a wide range of frequencies, including theta and gamma
(Szabadics et al., 2001; Blatow et al., 2003), recently have been
proposed to control cortical excitability by contributing to the
termination of up states in layer II/III (Fanselow and Connors,
2010). Additionally, as opposed to other interneuron subtypes,
LTS interneurons respond robustly to metabotropic glutamate
receptor (mGluR) activation (Beierlein et al., 2000; Fanselow
et al., 2008; Paluszkiewicz et al., 2011b). This robust activation of
LTS interneurons is reduced in Fmr1 KO mice compared to wild
type animals (Paluszkiewicz et al., 2011b). The decreased activa-
tion of LTS interneurons in Fmr1 KO mice reduces inhibitory out-
put which in turn alters the synchronization and spike output of
excitatory neuronal networks in layer II/III (Paluszkiewicz et al.,
2011b). It is also reported that unitary IPSC amplitude mediated
by LTS interneurons is increased in somatosensory cortex of
Fmr1 KO mice (Gibson et al., 2008). The fact that this powerful
subpopulation of interneurons are tightly coupled by gap junc-
tions (Beierlein et al., 2000; Deans et al., 2001) provides further
evidence that the LTS interneuronal microcircuits likely play a
key role in hyperexcitable and network synchrony abnormalities
in FXS. Moreover, on a network level, LTS interneurons engage
in theta frequency activity during mGluR activation (Fanselow
et al., 2008; Bostrom et al., 2013) which would explain elevated
theta power in EEG from FXS patients (Van der Molen and Van
der Molen, 2013).
There is additional evidence that suggest a role for interneu-
rons in FXS with respect to specific activation via neuromod-
ulators. Inhibitory interneurons have differential response to
neuromodulators, among them, acetylcholine muscarinic recep-
tors (Cea-del Rio et al., 2010), nicotinic receptors (Bell et al.,
2011), serotonin (Chittajallu et al., 2013) and endocannabinoids
(eCB; Glickfeld and Scanziani, 2006; Lee et al., 2010). This sug-
gests that alteration of neuromodulatory mechanisms in FXS
could differentially affect interneuron cell types. For instance,
loss of FMRP broadly affects the eCB signaling system through
local 2-arachidonoyl-sn-glycerol (2AG) diminished production
(Maccarrone et al., 2010; Zhang and Alger, 2010), possibly
because of impaired mGluR5-dependent 2AG formation (Jung
et al., 2012). Thus, defects of eCB production will affect inhibitory
processes through depolarization suppression of inhibition (DSI;
Lee et al., 2010) and slow self-inhibition (SSI; Bacci et al.,
2004) mechanisms, suggesting the participation of different set
of interneuron cell types in FXS neuronal network abnormalities,
including basket cells and LTS cells in the cortex (Bacci et al.,
2004; Lee et al., 2010) and basket cells and Schaffer collateral
interneurons in the hippocampus (Glickfeld and Scanziani, 2006;
Lee et al., 2010). Also, serotonin receptors are affected in the Fmr1
KO mouse model (Xu et al., 2012b), which can suggest differential
regulation of interneuronal cell types such as oriens-laconosum
moleculare (O-LM) interneurons of the hippocampus (Chitta-
jallu et al., 2013). Finally, molecular markers such as neuronal
nitric oxide synthetase and calbindin are downregulated in FXS
(Real et al., 2011; Xu et al., 2012a; Giráldez-Pérez et al., 2013),
which suggest that interneurons such as ivy cells, neurogliaform
cells (NGF) and bipolar interneuron populations can be dimin-
ished in brain circuits of FXS. From these initial studies in the field
it is apparent that both monosynaptic and polysynaptic mecha-
nisms of inhibition likely explain some of the neuropathologies
observed in FXS. Therefore, more efforts should be addressed
to identify specific interneuron populations participating in this
syndrome and their roles on network computing and synaptic
communication.
Interestingly, inhibitory neurotransmission dysfunction
appears to be region selective. As stated above, studies in the
cerebral cortex reveal interneuron specific problems. There is
a clear lack of excitatory drive to FS interneurons in layer IV
(Gibson et al., 2008) and faulty mGluR-dependent activation
of LTS interneurons in layer II/III (Paluszkiewicz et al., 2011b).
In contrast, inhibitory dysfunction in the amygdala appears to
be a “global” loss of inhibitory drive of both phasic (synaptic)
and tonic (extrasynaptic) inhibitory neurotransmission onto
excitatory principal neurons (Olmos-Serrano et al., 2010;
Vislay et al., 2013; Martin et al., 2014). There is also a lack
of immunostaining for the synthetic enzyme for GABA and
decreased inhibitory connections in the amygdala (Olmos-
Serrano et al., 2010). There are biochemical similarities in
interneuronal subtypes in the cortex and amygdala, however,
there are unique differences to specific spiking properties of
specific subtypes such as the parvalbumin-positive interneurons
in the amygdala (Woodruff and Sah, 2007a,b). Whether these
regional differences are the result of different developmental
and migratory patterns of interneuronal populations has yet
to be identified. Therefore, further investigation into specific
abnormalities in amygdala interneuronal subtypes will need to be
explored in future studies in the Fragile-X amygdala.
In summary, while enhanced excitatory neurotransmission
leads to hyperexcitable phenotypes, inhibitory interneurons are
not just contributing factors but are likely playing a major role
in hyperexcitable, hyperresponsiveness and hypersynchronicity
of neuronal networks in FXS (Gibson et al., 2008; Hays et al.,
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2011; Paluszkiewicz et al., 2011b; Gonçalves et al., 2013; Patel
et al., 2013). Principally, somatic and dendritic targeting FS and
LTS interneurons seem to be the more relevant cell types in
cortical abnormalities (Gibson et al., 2008; Paluszkiewicz et al.,
2011b), however we cannot rule out the participation of other
cortical interneuron cell types such as chandelier, double bouquet,
Martinotti or NGFs. Concurrently, interneurons could operate in
a different manner depending on the context in which they are
involved, from that point of view it is of high priority to study
the role of interneurons in different brain areas than the cortex in
order to understand their role in these other neuronal networks.
In this regard, studies in the Fragile-X amygdala showed that in
conditional KO animals, where FMRP is exclusively expressed in
inhibitory interneuron populations, that inhibitory neurotrans-
mission dysfunction is comprised of both presynaptic and post-
synaptic components (Vislay et al., 2013); therefore suggesting an
important role of interneurons in the development and function
of this particular brain region in FXS (Olmos-Serrano et al., 2010;
Vislay et al., 2013).
CONCLUDING REMARKS
Since many FXS patients also present with one or more features
of ASDs, insights gained from studying the monogenic basis of
FXS could pave the way to a greater understanding of the role
of inhibitory interneurons in autism. At this point most of the
evidence for interneuron participation is indirect in terms of
neuromodulatory activation and downstream excitatory network
activation, but very promising in terms of the relevance of their
contribution. Thus, understanding how interneurons participate
in neuronal network abnormalities seen in FXS lends to a greater
understanding for neurodevelopmental disorders that fall in the
autism spectrum.
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